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utcomes With the Paclitaxel-Eluting
tent in Patients With Acute Coronary Syndromes
nalysis From the TAXUS-IV Trial
effrey W. Moses, MD, FACC,*† Roxana Mehran, MD, FACC,*† Eugenia Nikolsky, MD,*†
ohn M. Lasala, MD, FACC,‡ Woodrow Corey, MD, FACC,§ Glenn Albin, MD, FACC,
ary Hirsch, MD, FACC,¶ Martin B. Leon, MD, FACC,*† Mary E. Russell, MD, FACC,#
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OBJECTIVES We sought to investigate the outcomes of paclitaxel-eluting stent implantation in patients
with unstable angina or non–ST-segment elevation myocardial infarction undergoing
percutaneous coronary intervention (PCI).
BACKGROUND Whether the paclitaxel-eluting stent is safe and effective in patients with acute coronary
syndromes (ACS) is unknown.
METHODS In the TAXUS-IV trial, 1,314 patients with stable or unstable ischemic syndromes undergoing
PCI were randomized to treatment with either the slow-release, polymer-based, paclitaxel-eluting
TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts).
The results were stratified by the acuity of the presenting clinical syndrome.
RESULTS Acute coronary syndromes were present in 450 patients (34.2%), 237 of whom were assigned
to paclitaxel-eluting stents and 213 to bare-metal stents. The baseline and procedural
characteristics were well matched between the groups. Clinical outcomes at 30 days were
similar with both stents. At one-year follow-up, patients with ACS assigned to the
paclitaxel-eluting stent compared to the control stent had strikingly lower rates of target
lesion revascularization (TLR) (3.9% vs. 16.0%, p 0.0001) and major adverse cardiac events
(11.1 vs. 21.7%, p  0.002). By multivariate analysis, ACS was an independent predictor of
in-stent restenosis in the cohort treated with bare-metal stents (hazard ratio [HR]  2.03
[95% confidence interval (CI) 1.05 to 3.92], p  0.035), while among patients randomized
to the paclitaxel-eluting stents, ACS was an independent predictor of freedom from restenosis
(HR  0.27 [95% CI 0.08 to 0.97], p  0.04).
CONCLUSIONS The use of the paclitaxel-eluting TAXUS stent was safe in patients with unstable ischemic
syndromes, and was associated with marked reduction of ischemia-driven TLR and adverse
cardiac events at one year. (J Am Coll Cardiol 2005;45:1165–71) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.074College of Cardiology Foundation
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Tcute coronary syndromes (ACS) account for over one
illion hospital admissions in the U.S. annually and,
herefore, represent a major public health concern (1).
ompelling evidence from recent randomized clinical trials
as demonstrated that intermediate- and high-risk patients
ith ACS derive significant reduction in both morbidity
nd mortality with an early invasive strategy (2–4). As a
esult, percutaneous coronary intervention (PCI) has be-
ome a standard treatment modality for many patients with
CS. Continued technical evolution of catheter-based pro-
edures including coronary stents combined with aggressive
From *Columbia University Medical Center, New York, New York; †The
ardiovascular Research Foundation, New York, New York; ‡Washington University
chool of Medicine, St. Louis, Missouri; §Community Hospitals of Indianapolis,
ndianapolis, Indiana; Saint Mary’s Hospital, Duluth, Minnesota; ¶Valley Hospital,
idgewood, New Jersey; #Boston Scientific Corp., Natick, Massachusetts; and the
*Cleveland Clinic Foundation, Cleveland, Ohio. Drs. Lasala, Ellis, and Stone have
erved as consultants for Boston Scientific, and Dr. Russell is an employee of and
quity holder in Boston Scientific.w
Manuscript received June 28, 2004; revised manuscript received October 18, 2004,
ccepted October 25, 2004.ntiplatelet and antithrombin therapy has resulted in signif-
cantly improved short- and intermediate-term clinical out-
omes (4,5). However, due to in-stent restenosis, the rate of
ne-year clinical events in patients with ACS still remains as
igh as 20%, contributing to patient morbidity and in-
reased health care resource consumption (6,7).
Recently, several randomized clinical trials have demon-
trated the ability of drug-eluting stents to profoundly
uppress in-stent neointimal hyperplasia, the main patho-
ogical substrate for in-stent restenosis, and to dramatically
educe clinical and angiographic restenosis (8–11). Whether
hese devices are safe and effective in patients with ACS, in
hom plaque rupture and thrombus formation is often
resent, is unknown (12). Therefore, we examined the
utcomes of patients presenting with unstable angina and
on–ST-segment elevation myocardial infarction (MI) in
he prospective, double-blind, randomized, multicenter
AXUS-IV trial comparing the paclitaxel-eluting stent
ith a bare-metal stent.
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he TAXUS-IV protocol, inclusion and exclusion criteria,
nd principal results have been recently reported (11).
riefly, 1,314 patients of at least 18 years of age with stable
r unstable ischemic syndromes undergoing PCI for a single
e novo lesion in a native coronary artery were randomized
o treatment with either the slow-release, polymer-based,
aclitaxel-eluting stent (TAXUS, Boston Scientific Corp.,
atick, Massachusetts) or a visually indistinguishable bare-
etal stent (EXPRESS, Boston Scientific, Corp.). Inclusion
riteria required a lesion with visually estimated length of 10 to
8 mm, and reference vessel diameter of 2.5 to 3.75 mm.
eneral eligibility criteria for enrollment have been described
reviously (11). Specifically, in regards to the present analysis,
linical syndrome acuity was not an exclusion criteria, and
atients with ACS (unstable angina or recent non–ST-
egment elevation MI) were encouraged for recruitment.
owever, patients with occluded coronary vessels (Thrombol-
sis In Myocardial Infarction flow grade 0/1) and obvious
ngiographic thrombus were excluded, as were those with
cute ST-segment elevation MI. At the time of the procedure,
he creatine kinase (CK)-MB level had to be 2  the local
aboratory’s upper limits of normal. An elevated troponin level
as not an exclusion criterion.
Before catheterization, patients received 325 mg aspirin and
00 mg of clopidogrel. Unfractionated heparin was adminis-
ered during the PCI per standard practice. After the proce-
ure, patients were maintained on aspirin 325 mg daily
ndefinitely and clopidogrel 75 mg daily for at least six months.
ll other treatments, including platelet glycoprotein IIb/IIIa
eceptor inhibitors, were at the discretion of the physicians,
hether before, during, or after the procedure.
Follow-up angiography at nine months was completed in
59 patients of a pre-specified cohort of 732 patients.
linical follow-up was scheduled at one, four, and nine
onths, at one year, and yearly thereafter for five years. The
nd points have been previously defined, and were all
djudicated by an independent clinical events committee.
ll baseline and follow-up films were analyzed at an
ndependent angiographic core laboratory blinded to clinical
vents. Major adverse cardiac events (MACE) were defined
s death from cardiac causes, MI, or ischemia-driven target
essel revascularization (TVR). Unstable angina was cate-
Abbreviations and Acronyms
ACS  acute coronary syndrome
CI  confidence interval
CK  creatine kinase
HR  hazard ratio
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
TLR  target lesion revascularization
TVR  target vessel revascularizationorized according to the Braunwald classification that takes tnto account the severity of angina (class I to III) and clinical
ircumstances related to the occurrence of the angina (class
, B, and C, corresponding to angina developing in the
resence or absence of an extracardiac condition or within
wo weeks of acute MI, respectively) (13). Non–ST-
egment elevation MI before PCI was defined as a CK-MB
r troponin level greater than the upper limit of normal
ithout evidence of acute ST-segment elevation MI.
tatistical methods. Categorical variables were compared
ith the Fisher exact test for pairwise comparisons or
hi-square test for trend for multiple group comparisons.
ontinuous variables are presented as mean  SD, and
ere compared using the Student t test. Survival estimated
ere created using Kaplan-Meier methodology and com-
ared with the log-rank test. Multivariate analysis of pre-
ictors of TVR were identified using Cox proportional
azards regression with stepwise selection using entry and
xit criteria of p  0.1. The candidate variables entered in
he model included age, gender, angina status (unstable vs.
ot unstable), diabetes mellitus, hypertension, hyperlipid-
mia, current smoking, history of MI, creatinine clearance,
eft anterior descending artery target vessel, ejection frac-
ion, randomization to paclitaxel-eluting stent, stent length
nd diameter, total length of the stented segment, amount
f stents, the use of non-study stents, balloon-to-artery
atio, target vessel reference diameter, and target vessel
ngulation.
ESULTS
aseline characteristics. Acute coronary syndrome was
resent in 450 of the 1,314 enrolled patients (34.2%); 237
atients (201 patients with unstable angina and 36 patients
ith non–ST-segment elevation MI) were assigned to
aclitaxel-eluting stents and 213 patients (186 and 27
atients, respectively) to bare-metal stents. As seen in Table 1,
he baseline clinical and angiographic features of patients
ith ACS were well matched between the two randomized
roups, including the severity of angina, with approximately
wo-thirds of patients in each group having angina at rest
class IIB/C or IIIB/C), and about one-third of patients
aving angina at rest within the preceding 48 h (class
IIB/C). Approximately 20% of patients in both groups
resented with non–ST-segment elevation MI. Pre-
rocedure medication use was similar in the two groups
ith virtually all patients treated with aspirin and clopi-
ogrel, two-thirds treated with beta-blockers, and approxi-
ately one-third of the patients treated with either unfrac-
ionated or low-molecular-weight heparin. Pre-procedural
latelet glycoprotein IIb/IIIa receptor inhibitors were ad-
inistered in 10% of patients.
rocedural results. Procedural characteristics did not differ
ignificantly between the ACS patients treated with
aclitaxel-eluting and bare-metal stents (Table 2). Platelet
lycoprotein IIb/IIIa receptor inhibitors were administered
o more than one-half of the patients in both groups, with
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espectively), eptifibatide (33.8% vs. 31.5%, respectively),
nd tirofiban (5.9% vs. 5.6%, respectively).
linical outcomes. As seen in Table 3, there were no
ignificant differences in 30-day clinical end points between
atients with ACS treated with paclitaxel-eluting stents
ompared to bare-metal stents. At one-year follow-up,
owever, use of the paclitaxel-eluting stent in patients with
CS was associated with a reduction in target lesion
evascularization (TLR) by 78% (95% confidence interval
CI] 53% to 89%), TVR by 65% (95% CI 35% to 81%) and
omposite MACE by 51% (95% CI 21% to 70%) (Fig. 1).
n addition, a trend was present toward a 37% reduction in
he rate of MI at one year in patients with unstable angina
r non–ST-segment elevation MI treated with paclitaxel-
Table 1. Baseline Clinical Characteristics and
Coronary Syndromes
Clinical characteristics
Age (yrs)
Male gender
Braunwald unstable angina class
IB
IC
IIB
IIC
IIIB
IIIC
Non–ST-segment elevation myocardial infarction
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoking
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Pre-procedure medications
Aspirin
Clopidogrel or ticlopidine
Unfractionated heparin
Low-molecular-weight heparin
Glycoprotein IIb/IIIa inhibitors
Beta-blocker
ACE inhibitor
Lipid-lowering agents
Angiographic features
TIMI flow grade 3
Lesion length (mm)
Reference vessel diameter (mm)
Minimal luminal diameter (mm)
Diameter stenosis (%)
Left ventricular ejection fraction (%)
Target artery
Left anterior descending artery
Left circumflex artery
Right coronary artery
ACE  angiotensin-converting enzyme; TIMI  Thromboluting stent. A total of four patients developed stent mhrombosis: two patients were treated with paclitaxel-
luting stents (both received glycoprotein IIb/IIIa receptor
nhibitors during the index procedure), and two patients
ere treated with bare-metal stents (neither of whom
eceived platelet glycoprotein IIb/IIIa receptor inhibitors).
By multivariate analysis, assignment to the paclitaxel-
luting stent in patients with ACS was a significant inde-
endent predictor of freedom from one-year TVR (hazard
atio [HR]  0.40 [95% CI 0.28 to 0.57], p  0.0001).
ngiographic outcomes. Among patients with ACS, 101
atients treated with paclitaxel-eluting stents and 87 pa-
ients treated with bare-metal stents completed nine-month
ngiographic follow-up. Patients assigned to receive the
aclitaxel-eluting stent had significantly less late loss both
n-stent and within the analysis segment resulting in a
ographic Features in Patients With Acute
Paclitaxel-Eluting
Stent
(n  237)
Bare-Metal
Stent
(n  213) p Value
62.7  11.5 61.2  11.4 0.17
66.7% 64.8% 0.69
29.1% 34.3% 0.26
3.4% 1.9% 0.39
25.7% 24.4% 0.83
3.8% 5.6% 0.38
30.8% 28.6% 0.68
7.2% 4.7% 0.32
20.7% 17.9% 0.57
26.6% 23.0% 0.38
68.4% 71.4% 0.54
65.4% 66.0% 0.92
29.6% 29.7% 1.00
37.1% 40.8% 0.44
31.2% 34.8% 0.47
11.0% 10.8% 1.00
100% 98.6% 0.10
98.7% 99.5% 0.63
19.4% 17.4% 0.62
17.7% 12.7% 0.15
9.7% 7.0% 0.39
70.0% 73.2% 0.46
49.4% 47.4% 0.70
65.4% 69.5% 0.37
5.5% 3.8% 0.69
14.2  6.5 14.1  6.4 0.87
2.80  0.48 2.80  0.50 0.97
0.91  0.33 0.90  0.30 0.87
67.3  11.1 67.6  9.6 0.83
55.1  9.7 53.3  10.9 0.07
38.4% 38.7% 1.00
29.5% 30.2% 0.92
32.1% 31.1% 0.84
n Myocardial Infarction.Angi
lysis Iarked 87% reduction of in-stent and 86% reduction of
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ccur after TAXUS stent implantation, it was nearly always
ocal in nature and significantly shorter in length than after
are-metal stents.
aclitaxel-eluting stent arm: patients with stable versus
nstable ischemic syndromes. The outcomes of the 237
atients with ACS treated with paclitaxel-eluting stent were
urther compared to the 425 patients with stable ischemic
yndromes also treated with the TAXUS stent. Patients
ith ACS compared to those with stable ischemic syn-
romes were more commonly female (33.3% vs. 25.4%, p
.03) and current smokers (29.6% vs. 21.2%, p 0.02), had
higher incidence of previous MI (37.1% vs. 26.8%, p 
.006), and were more commonly treated before the proce-
ure with unfractionated heparin (19.4% vs. 6.4%, p 
.0001), low-molecular-weight heparin (17.7% vs. 4.5%,
Table 2. Procedural Results in Patients With A
Pac
Number of study stents 1
Maximal stent diameter (mm) 3
Maximal balloon/artery ratio 1
Stent length (mm) 2
Use of glycoprotein IIb/IIIa inhibitors
Final TIMI flow grade 3
Final reference vessel diameter (mm) 2
Final minimal luminal diameter (mm)
Analysis segment
In-stent 2
Final diameter stenosis (%)
Analysis segment 1
In-stent 4
Acute gain
Analysis segment 1
In-stent 1
TIMI  Thrombolysis In Myocardial Infarction.
Table 3. Clinical Outcomes in Patients With A
Paclitax
S
(n 
Cardiac death
30-day (%)
1-year (%)
Myocardial infarction
30-day (%)
1-year (%)
Target lesion revascularization
30-day (%)
1-year (%)
Target vessel revascularization
30-day (%)
1-year (%)
Composite major adverse events
30-day (%)
1-year (%) 1
Stent thrombosis
30-day (%)
1-year (%) 0.8% 0.0001), platelet glycoprotein IIb/IIIa receptor inhib-
tors (9.7% vs. 4.0%, p  0.006), beta-blockers (70.0% vs.
8.6%, p  0.004), and nitrates (55.3% vs. 28.7%, p 
.0001).
Patients with ACS compared to those with stable isch-
mic syndromes treated with the TAXUS stent had a trend
oward a higher rate of stent thrombosis at 30 days (0.8% vs.
.0%, p  0.06), but not at 1 year (0.8% vs. 0.5%,
espectively, p  0.55). There was no formal interaction,
owever, between clinical syndrome acuity (ACS vs. non-
CS) and randomization to the TAXUS stent rather than
he bare-metal control stent on the occurrence of stent
hrombosis at either 30 days or 1 year (Breslow-Day test for
omogeneity p  0.23 and 0.89, respectively).
As seen in Figure 2, the one-year rates of cardiac death
ended to be higher in patients with ACS compared to those
Coronary Syndromes
l-Eluting
nt
237)
Bare-Metal
Stent
(n  213) p Value
0.31 1.10  0.31 0.97
0.33 3.05  0.32 0.59
0.17 1.18  0.16 0.57
8.6 22.5  9.2 0.98
6% 57.3% 0.77
7% 100.0% 0.25
0.46 2.78  0.52 0.57
0.45 2.25  0.49 0.54
0.42 2.62  0.43 0.21
9.5 20.1  9.9 0.14
10.49 7.07  11.42 0.11
0.48 1.37  0.48 0.71
0.46 1.74  0.44 0.29
Coronary Syndromes
uting
)
Bare-Metal
Stent
(n  213) p Value
0.5% 0.62
2.0% 0.63
2.3% 0.91
6.2% 0.27
0.5% 0.29
16.0% 0.0001
0.5% 0.29
17.7% 0.0003
2.3% 0.52
21.7% 0.003
0.5% 0.63cute
litaxe
Ste
(n 
.09 
.07 
.17 
2.5 
58.
98.
.81 
2.2 
.67 
8.3 
.93 
.38 
.78 cute
el-El
tent
237
0.8%
2.5%
2.5%
3.8%
0.0%
3.9%
0.0%
6.5%
3.4%
1.1%
0.8%
0.9% 0.91
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tent. The rates of MI at one-year follow-up were similar
etween the two groups, as was TVR and MACE. Binary
nalysis segment restenosis rates in patients treated with the
AXUS stent were 5.0% in patients with ACS compared to
.5% in non-ACS (p  0.25). Analysis segment late loss
fter TAXUS stent placement also did not differ significantly
etween patients with and without ACS (0.19 0.41 mm vs.
.25  0.45 mm, respectively, p  0.23). By multivariate
nalysis, presentation with ACS was an independent pre-
ictor of freedom from restenosis among patients randomized
o the TAXUS stent (HR  0.27 [95% CI 0.08 to 0.97],
 0.044).
igure 1. Cumulative risk of major adverse cardiac events in patients with
cute coronary syndromes treated with paclitaxel-eluting stents versus
are-metal stents.
Table 4. Angiographic Follow-Up in Patients
Paclita
S
(n
Reference vessel diameter (mm) 2.80
Minimal luminal diameter (mm)
Analysis segment 2.33
In-stent 2.68
Stenosis (% of luminal diameter)
Analysis segment 18.1
In-stent 5.1
Late loss (mm)
Analysis segment 0.19
In-stent 0.34
Late loss index (mm)
Analysis segment 0.12
In-stent 0.19
Binary restenosis rate (%)
Analysis segment
In-stent
Patterns of restenosis (%)
Focal
Diffuse
Proliferative
Total occlusionLength of restenosed lesion (mm) 7.64  2.are-metal stent arm: patients with stable versus unsta-
le ischemic syndromes. The baseline characteristics of
atients with versus without ACS treated with bare-metal
tents differed in a similar fashion as for this comparison
ith paclitaxel-eluting stents. Compared with the 213
atients with ACS treated with bare-metal stents, the 439
atients with stable ischemic syndromes treated with the
are-metal stent had similar rates of stent thrombosis at 30
ays (0.5% vs. 0.7%, respectively, p  0.74) and 1 year
0.9% vs. 0.7%, respectively, p  0.73). As seen in Figure 2,
he rates of cardiac death, MI, TVR, and MACE were also
ot significantly different at one year. Binary restenosis in
he analysis segment occurred in 21.7% in patients with
CS compared to 30.2% in patients without ACS treated
ith bare-metal stents (p  0.13). Analysis segment late
oss also did not differ significantly between the patients
ith and without ACS treated with bare-metal stents (0.69
0.56 mm vs. 0.58 0.58 mm, respectively, p 0.15). By
ultivariate analysis, among patients randomized to the
are-metal control stent, the presence of ACS at baseline
as an independent predictor of restenosis (HR  2.03
95% CI 1.05 to 3.92], p  0.035).
ISCUSSION
he major results of this analysis from the TAXUS-IV
andomized trial are: 1) implantation of the polymer-based
aclitaxel-eluting TAXUS stent in ACS was safe, without
ncreased rates of cardiac death, MI, or stent thrombosis
ompared to bare-metal stent implantation; 2) TAXUS
tent implantation in patients with both ACS and non-
CS was associated with a marked reduction in clinical
Acute Coronary Syndromes
luting
2)
Bare-Metal
Stent
(n  87) p Value
48 2.80  0.50 0.97
44 2.25  0.49 0.27
42 2.62  0.40 0.28
9 20.9  9.9 0.04
.7 7.4  11.5 0.15
41 0.69  0.56 0.0001
44 0.95  0.59 0.0001
33 0.50  0.48 0.0001
28 0.56  0.36 0.0001
34.5% 0.0001
30.2% 0.0001
9.3% 0.11
17.4% 0.0001
3.5% 0.09
0.0% —With
xel-E
tent
 10
 0.
 0.
 0.
 8.
 10
 0.
 0.
 0.
 0.
5.0%
4.0%
3.0%
1.0%
0.0%
0.0%62 16.55  10.15 0.0004
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Paclitaxel Stent in Acute Coronary Syndromes April 19, 2005:1165–71estenosis (TLR), with enhanced event-free survival com-
ared to patients receiving a bare-metal stent; and 3) the
AXUS stent resulted in significant reductions in neointi-
al tissue proliferation and restenosis regardless of clinical
yndrome acuity.
The thrombogenic coronary milieu in patients with
nstable angina (12,14), coupled with a theoretical propen-
ity for hypercoagulability and delayed re-endothelialization
ith drug-eluting stents, has resulted in concerns of an
ncreased risk of stent thrombosis after implantation of
hese devices in patients with ACS. In this regard, a trend
as present for an increased rate of stent thrombosis with
he paclitaxel-eluting stent at 30 days in patients with
nstable compared to stable ischemic syndromes in the
resent study. However, this difference represented two
uch events in the TAXUS arm versus zero in the control
rm, and no such difference was present at one year.
oreover, there were no differences in stent thrombosis
ates between patients treated with paclitaxel-eluting versus
are-metal stents within the cohort with ACS at any time
eriod, nor were rates of MI or mortality increased with the
aclitaxel-eluting stent compared to control in patients with
CS. Thus, from the available data, implantation of the
AXUS stent appears to be safe in both patients with stable
nd unstable ischemic syndromes, though additional studies
ith greater numbers of TAXUS implants in ACS are
arranted, especially in patients excluded from randomiza-
ion, such as those with acute ST-segment elevation MI and
ngiographically evident thrombus.
Similar to patients with stable ischemic syndromes, the
se of paclitaxel-eluting stents in patients with ACS re-
ulted in strikingly reduced rates of nine-month TLR (74%
s. 72%; p  0.50), TVR (65% vs. 54%; p  0.63), and
ngiographic restenosis (58% vs. 85%; p  0.03). Notably,
n patients with ACS, the TVR rate in patients treated with
he TAXUS stent was almost unchanged from nine months
6.1%) to one year (6.5%), whereas the TVR rate continued
o increase during this period in patients treated with
igure 2. One-year clinical outcomes in patients with unstable and stable
schemic syndromes treated with paclitaxel-eluting versus bare-metal
tents. MACE  major adverse cardiac events; TVR  target vessel
evascularization.are-metal stents (from 13.2% to 17.7%, respectively). Timilarly, the composite MACE rate was stable between
ine months and one year (10.6% vs. 11.1%), but continued
o increase in patients treated with bare-metal stents (from
6.4% to 21.7%). Of note, a numerically higher incidence of
I in addition to more revascularization procedures con-
ributed to the incremental rise in adverse events in patients
reated with bare-metal stents. Thus, the benefits of the
AXUS stent relative to the bare-metal control in patients
ith ACS are increasing with longer duration of follow-up
as previously described in the entire study population [15]).
Several prior studies have identified unstable angina as
risk factor for restenosis after bare-metal stent implan-
ation (6,7). Major adverse cardiac events after bare-
etal stenting are also increased in patients presenting
ith ACS compared to stable angina (16). In the present
tudy, however, early and late TVR and MACE rates
ere similar in patients with and without ACS. Of
nterest, however, ACS was an independent predictor of
n-stent restenosis in the cohort treated with bare-metal
tents, whereas the presence of ACS was paradoxically an
ndependent correlate of a reduced risk of restenosis in
atients treated with the TAXUS stent. The local influ-
nce of paclitaxel in reducing both inflammatory and
roliferative responses might account for more pro-
ounced beneficial effects of this device in patients with
nstable compared with stable angina (17). Additional
tudies are required to confirm this possibility.
tudy limitations. This post-hoc analysis was not pre-
pecified in the original trial design and, thus, must be
onsidered hypothesis-generating. No conclusions can be
rawn regarding patients excluded from randomization,
ncluding those with a CK-MB level 2  the upper limits
f normal at the time of the index PCI, angiographic
vidence of definite thrombus, and acute ST-segment ele-
ation MI, all of which are risk factors for adverse outcomes
18). The extent to which the prolonged (at least six-month)
ourse of thienopyridines contributed to the beneficial
utcomes in patients with ACS in the present study is
nknown (19,20). Inflammatory biomarkers as well as
ardiac enzymes other than creatine phosphokinase isoen-
ymes were not routinely collected, nor were admission
lectrocardiograms analyzed at a core laboratory; in-depth
isk stratification of the patients was, therefore, not possible.
onetheless, more than 65% of the patients with ACS were
raunwald class II or III, indicating high risk (21). The
esults of the present study are, therefore, applicable to the
ajority of patients with ACS, excepting those at the
ighest risk.
onclusions and clinical implications. In this substudy of
he TAXUS-IV randomized trial, the use of the paclitaxel-
luting TAXUS stent was safe in most patients with ACS,
nd was associated with markedly reduced ischemia-driven
LR, TVR, and MACE at one year. Thus, patients with
CS who otherwise meet the inclusion criteria for the
AXUS-IV study will have superior outcomes with prefer-
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